A股異動 | 多氟多(002407.SZ)漲約4% 控股子公司陽福新材料引入韓國Enchem為戰投
格隆匯2月11日丨多氟多(002407.SZ)漲約4%,報43.1元,總市值330億元。多氟多昨晚發佈公吿稱,其控股子公司多氟多陽福新材料有限公司通過增資擴股方式引入戰略投資者。韓國上市公司Enchem Co.,Ltd.同意按照協議約定以人民幣2.76億元認購陽福新材料新增註冊資本4439.63萬元,取得增資後陽福新材料15%的股權,其餘2.31億元增資款計入資本公積。本次子公司引進戰略投資者進行增資擴股有助於增強子公司資金實力,進一步提升競爭和抗風險能力,促進子公司業務發展,強化新材料業務,提升公司的市場佔有率,對公司保持市場領先地位具有積極意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.